Pfizer Inc. $PFE Shares Acquired by Benjamin Edwards Inc.

Benjamin Edwards Inc. increased its holdings in Pfizer Inc. (NYSE:PFE) by 17.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 237,703 shares of the biopharmaceutical company’s stock after purchasing an additional 35,243 shares during the period. Benjamin Edwards Inc.’s holdings in Pfizer were worth $5,724,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Godfrey Financial Associates Inc. acquired a new stake in Pfizer in the 4th quarter worth about $26,000. Keb Asset Management LLC acquired a new position in shares of Pfizer during the 2nd quarter valued at about $26,000. Field & Main Bank purchased a new position in shares of Pfizer during the 2nd quarter worth about $27,000. HFM Investment Advisors LLC lifted its holdings in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. boosted its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 0.0%

Shares of Pfizer stock opened at $27.95 on Monday. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The stock has a market cap of $159.31 billion, a price-to-earnings ratio of 36.78 and a beta of 0.34. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The company has a fifty day moving average price of $25.55 and a 200 day moving average price of $26.30.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company posted $0.78 earnings per share. The firm’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.2%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Weiss Ratings lowered shares of Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, August 17th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and lowered their price objective for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Finally, Guggenheim cut their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.28.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article
• Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article
• Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update
• Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article
• Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article
• Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.